Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors

Not Applicable

Completed

Conditions: Fatigue
Breast Cancer
Cancer Survivor
Long-term Effects Secondary to Cancer Therapy in Adults
Psychosocial Effects of Cancer and Its Treatment

Interventions: Other: laboratory biomarker analysis
Behavioral: exercise intervention
Other: questionnaire administration
Other: survey administration
Procedure: assessment of therapy complications
Procedure: fatigue assessment and management
Procedure: management of therapy complications
Procedure: psychosocial assessment and care

First Posted Date: 2008-04-21

Last Posted Date: 2015-10-15

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 115

Registration Number: NCT00662103

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Exercise for Physical Health in Men With Prostate Cancer

Not Applicable

Completed

Conditions: Prostatic Neoplasm
Osteoporosis

Interventions: Behavioral: Flexibility Training
Behavioral: Resistance Exercise

First Posted Date: 2008-04-17

Last Posted Date: 2015-10-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 56

Registration Number: NCT00660686

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Not Applicable

Completed

Conditions: Adult Brain Glioblastoma

Interventions: Drug: Gadolinium
Drug: Ferumoxytol Non-Stoichiometric Magnetite
Other: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Other: Diffusion Weighted Imaging
Other: MRI-Based Angiogram

First Posted Date: 2008-04-17

Last Posted Date: 2017-05-16

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00660543

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Optimizing Body Composition & Health After Breast Cancer

Not Applicable

Completed

Conditions: Breast Neoplasm
Osteoporosis, Postmenopausal

Interventions: Behavioral: Flexibility Training
Behavioral: Resistance Exercise

First Posted Date: 2008-04-17

Last Posted Date: 2015-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 71

Registration Number: NCT00659906

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

Phase 2

Terminated

Conditions: Brain Neoplasms

Interventions: Drug: Ferumoxtran-10 (Combidex)
Procedure: Neurosurgery

First Posted Date: 2008-04-16

Last Posted Date: 2022-12-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 116

Registration Number: NCT00659334

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Phase 2

Terminated

Conditions: Metastatic Malignant Neoplasm in the Brain
Primary Brain Neoplasm

Interventions: Procedure: 3 Tesla Magnetic Resonance Imaging
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol
Drug: Gadolinium
Procedure: High Field Strength Magnetic Resonance Imaging
Procedure: Susceptibility Weighted Imaging

First Posted Date: 2008-04-16

Last Posted Date: 2023-09-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00659126

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Erlotinib
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2008-03-25

Last Posted Date: 2014-09-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00642746

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

Not Applicable

Completed

Conditions: Breast Cancer
Precancerous Condition

Interventions: Other: placebo
Dietary Supplement: omega-3 fatty acid

First Posted Date: 2008-03-03

Last Posted Date: 2017-04-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00627276

Locations: 🇺🇸
Epic Imaging, Portland, Oregon, United States
🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Molecular Markers in Thyroid Cancer

Completed

Conditions: Thyroid Cancer

First Posted Date: 2008-01-21

Last Posted Date: 2014-12-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 847

Registration Number: NCT00598364

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Strength Training for Older Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Neoplasm
Osteoporosis, Postmenopausal

Interventions: Behavioral: Resistance Exercise
Behavioral: Flexibility Training

First Posted Date: 2008-01-11

Last Posted Date: 2015-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 106

Registration Number: NCT00591747

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy